Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods

Cyclosporine is used in the prevention of allograft rejection. Owing to its narrow therapeutic index, regular monitoring of the whole blood levels of cyclosporine is required. We observed that immunoassays measured significantly higher cyclosporine levels than did high-performance liquid chromatogra...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical pathology 2000-10, Vol.114 (4), p.536-543
Main Authors: HAMWI, Ahmad, SALOMON, Alexandra, STEINBRUGGER, Richard, FRITZER-SZEKERES, Monika, JÄGER, Walter, SZEKERES, Thomas
Format: Article
Language:English
Subjects:
Biological and medical sciences
Bone Marrow Transplantation
Chromatography, High Pressure Liquid
Cyclosporine - metabolism
Cyclosporine - pharmacokinetics
Female
Heart-Lung Transplantation
Humans
Immunoassay - methods
Immunomodulators
Immunosuppressive Agents - metabolism
Immunosuppressive Agents - pharmacokinetics
Kidney Transplantation
Liver Transplantation
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cyclosporine is used in the prevention of allograft rejection. Owing to its narrow therapeutic index, regular monitoring of the whole blood levels of cyclosporine is required. We observed that immunoassays measured significantly higher cyclosporine levels than did high-performance liquid chromatography (HPLC) over time after transplantation. As cyclosporine metabolites cross-react even with immunoassays, this observation might be due to alterations of the cyclosporine metabolism. We analyzed cyclosporine metabolite concentrations in the early and in the late posttransplantation periods in 127 patients after kidney, bone marrow, heart-lung, and liver transplantation by HPLC and determined whole blood levels of cyclosporine by 4 immunoassays (enzyme-multiplied immunoassay [EMIT], cloned enzyme donor immunoassay [CEDIA], AxSYM [Abbott Laboratories, Chicago, IL], and TDx [Abbott Laboratories]). Despite reduced dose, we found significantly higher cyclosporine concentrations measured by the EMIT, AxSYM, and TDx assays in various patient groups. These results are due to the increased metabolite/cyclosporine ratio in the late posttransplantation period. In particular, the metabolites AM1 and AM19 increased significantly over time in bone marrow transplant recipients. Therefore, cyclosporine levels measured by immunoassays should be interpreted with caution.
ISSN:0002-9173
1943-7722
DOI:10.1309/8pgn-0c9e-3nb9-cjk5